


Management of Treatment-Naïve G1 Patients with F1 Fibrosis: Treat Now or Wait?

W. Ray Kim, MD

Professor and Chief

Gastroenterology and Hepatology

Stanford University School of Medicine




Case

50 year-old aircraft mechanic was diagnosed with hepatitis C (2007).

- Transmission route: Uncertain
- Duration of infection: Unknown
- Feeling well
- Normal exam except BMI 30
- Genotype 1a
- ALT: 154 IU/L, T. bilirubin: 0.9 mg/dL
- US: Mild increase in echogenicity. Negative otherwise.

LIVER BIOPSY:

- Minimal activity (grade 1)
- No fibrosis (stage 0)
- Mild steatosis



Question

Should this patient be treated?

Yes


No

Case

DECIDED NOT TO TREAT - OBSERVED.

Three years later (2010)


- No symptoms
- ALT: 280 IU/ml
- T. bili: 0.8 mg/dl
- Albumin: 4.5 g/dl
- Platelets: 124
- US: Diffuse fatty infiltration, mild splenomegaly



Triangle in HCV Management


Benefit

Toxicity




Cost

Factors affecting Treatment Outcome




Benefits of Early Intervention

Peg+Ribavirin era




Benefits of Early Intervention




Reasons to Wait

Chronic hepatitis C progresses slowly.



Cost-Effectiveness Ratios


£ per QALY





Reasons to Wait

Hepatitis C Treatment is improving rapidly.

Sofosbuvir + Ledipasvir +/- Ribavirin in G1 Naïve Non-cirrhotic



But...Better Not Wait Too Long



Case Follow-up

Initiated peg+R (2010)

- Tolerated full dose well
- Minimal hematological toxicity
- HCV RNA: 2.4 million iu (baseline) to 75 iu/ml (24 weeks)
- Treatment discontinued


Discussed but declined retreatment using Telaprevir

- Expected SVR = 15%

Participating in a sofosbuvir trial.


Steatosis and HCV Fibrosis

Consecutive clinic cohort (Napoli, Italy: n=180)



Management Decisions in HCV Therapy

Benefit - Risk comparison



Tx-Naïve G1 F1: Treat or Wait?

Most patients can wait.

Exceptions:

Unreliable assessment of fibrosis

High likelihood of progression

- HIV
- EtOH
- NAFLD

Transmission risk

Patient preference